搜索

CopyRight 2017 All Right Reserved  南京泽恒医药技术开发有限公司 备案号:苏ICP备10067022号 网站建设:中企动力 南京

  • k

新闻中心

Gary Spitzer, M.D.

浏览量

Chief Clinical Advisor

Dr. Gary Spitzer is a world-renowned oncologist who has vast experience in hematomalignancies and solid tumor malignancies. He was one of the early pioneers in bone marrow transplantation at M.D. Anderson Hospital, and directed hematology/oncology and bone marrow transplantation departments at St. Louis University and Georgetown University. He has also extensively published, with more than 300 manuscripts and articles. Dr. Spitzer has been a leader in the development of curative regimens for Hodgkin’s lymphoma and other hematologic malignancies of which we now consider standard of care, and in vitro studies of drug drug activity in solid tumors. Dr. Spitzer currently takes a very active role in clinical trials involving both solid tumor malignancies and hematopoeitic malignancies. In one of his current roles as clinical director of MolDx, he is well-versed in reviewing and assisting in the development of clinical utility studies for specialized genomic testing in cancer and clinical trials from the industry.

Dr. Spitzer received his M.B. and B.S. from the University of Melbourne. He has served on the boards for several specialties, including: the M.R.A.C.P.: Royal Australian College of Physicians, the American Board of Internal Medicine, the Medical Oncology Recertification, Recertification: Internal Medicine and Oncology, Medical Oncology.

He is currently Epic Emeritus Professor at Epis and Beacon Implementation for Oncology Services. Dr. Spitzer also serves as a consultant MOLDx, and Incyte Pharmaceuticals. He is the recipient of the Leukemia Society of America Scholarship and the Searle Traveling Scholarship.

Dr. Spitzer is the author of over one hundred peer-reviewed manuscripts and serves as a member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Bone and Marrow Transplantation, the American Society of Hematotherapy and Graft Engineering, and the American Society of Hematology.